|Bid||2.17 x 2200|
|Ask||2.60 x 38500|
|Day's Range||2.12 - 2.18|
|52 Week Range||0.63 - 4.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.67|
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of F.N.B. ...
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.
AVEO Oncology today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
AVEO Oncology today reported financial results for the full year ended December 31, 2017 and provided a business update.
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m.
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / U.S. markets spiked to session highs after minutes from the Fed's January meeting were released, but then dropped as yields for the 10-year Treasury note ...
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Stock Monitor: Bio-Techne Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on AVEO Pharma, Inc. (NASDAQ: AVEO ). If you ...
AVEO Oncology today announced that the United Kingdom’s National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA® for the first line treatment of adult patients with advanced renal cell carcinoma .